about
The fate of chemoresistance in triple negative breast cancer (TNBC)Estrogen Receptor-β and the Insulin-Like Growth Factor Axis as Potential Therapeutic Targets for Triple-Negative Breast Cancer.Adeno-associated virus type 2 infection of nude mouse human breast cancer xenograft induces necrotic death and inhibits tumor growth.The functional interaction between Acyl-CoA synthetase 4, 5-lipooxygenase and cyclooxygenase-2 controls tumor growth: a novel therapeutic target.Transforming growth factor-β, insulin-like growth factor I/insulin-like growth factor I receptor and vascular endothelial growth factor-A: prognostic and predictive markers in triple-negative and non-triple-negative breast cancer.Nomograms for Predicting the Prognostic Value of Pre-Therapeutic CA15-3 and CEA Serum Levels in TNBC Patients.In vitro and in vivo evaluation of novel anticancer agents in triple negative breast cancer models.Phemindole, a Synthetic Di-indole Derivative Maneuvers the Store Operated Calcium Entry (SOCE) to Induce Potent Anti-Carcinogenic Activity in Human Triple Negative Breast Cancer Cells.BRCA1 And BRCA2 analysis of Argentinean breast/ovarian cancer patients selected for age and family history highlights a role for novel mutations of putative south-American origin.5-FU and ixabepilone modify the microRNA expression profiles in MDA-MB-453 triple-negative breast cancer cellsMicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase.Receptors for Insulin-Like Growth Factor-2 and Androgens as Therapeutic Targets in Triple-Negative Breast Cancer.
P2860
Q26775232-07EF295E-1EC2-40C8-98D1-AB21F48ADD31Q33866151-3C8A8962-7027-493A-BC1E-600FAFFC21F6Q33989913-35AF05DF-AAB4-4315-A4CE-705ADF758B27Q34342416-B53ABB14-856D-48B2-87AE-E7D874DE45F2Q35628188-C2020C11-6AAB-43A6-8446-1D1F5031B5F1Q36113248-C745E5A6-9360-4777-AF9F-ABBAE2E3DBA4Q36773299-5D172975-411A-4057-8BFC-2789729A3B68Q36863681-7E00CEF2-AA8A-492D-AB90-22B83C5B1411Q37052120-632D5FFC-5F2C-40AF-8C95-ACB45599E44CQ37438076-9718D2D6-04EA-4530-AD59-4B5EC8C08FCEQ37706967-C043F5BC-1B16-450C-BBA1-34BAF074AED7Q46237958-57DCC4CA-7280-4871-80AF-E8CC2C15166C
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Management options in triple-negative breast cancer
@ast
Management options in triple-negative breast cancer
@en
type
label
Management options in triple-negative breast cancer
@ast
Management options in triple-negative breast cancer
@en
prefLabel
Management options in triple-negative breast cancer
@ast
Management options in triple-negative breast cancer
@en
P2093
P2860
P356
P1476
Management options in triple-negative breast cancer
@en
P2093
Christina A Minami
Debra U Chung
Helena R Chang
P2860
P304
P356
10.4137/BCBCR.S6562
P577
2011-07-27T00:00:00Z